GIP and type 2 diabetes mellitus: The SURPASS trials showed Tirzepatide, a dual GIP/GLP-1 receptor agonist, led to clinically significant weight loss in individuals with type 2 diabetes with an average weight reduction of 7–14% of body weight and a substantial proportion of participants achieving weight reductions of 15% or more [21].